Few biologics in the US have multiple biosimilar competitors, but originator biologics respond quickly to competition by ...

Biosimilars could improve access to biologic treatments and health care sustainability in Latin America, but their adoption ...

The European Commission grants marketing authorization to 2 aflibercept biosimilars; Biosimilars Canada launches new campaign ...

Although financial incentives introduced by Japan's 2022 health policy did not result in a reduction in overall drug costs, ...

Early adopters of biosimilars have paved the way for broader acceptance by sharing real-world success strategies, overcoming initial resistance, and highlighting best practices for integration and ...

A decade and a half after biosimilars were recognized in the US, we have only 16 products as multiple biosimilars, while more than 100 molecules await entry. This disappointment is highly touted by ...

On this special episode of Not So Different honoring Global Biosimilars Week, Craig Burton, executive director of the Biosimilars Council, explores how global policies—from incentives to health equity ...